Resultados financieros en millones de dólares estadounidenses. El ejercicio fiscal es febrero - enero.
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Ingresos
2,521
2,071
1,697
1,305
1,098
904
Crecimiento de los Ingresos (YoY)
27%
22%
30%
19%
21%
22%
Costo de los ingresos
719
625
537
499
346
322
Utilidad bruta
1,802
1,445
1,159
805
752
582
Venta, General y Administración
1,094
917
734
587
466
384
Investigación y Desarrollo
270
219
205
180
160
146
Gastos de Operación
1,365
1,136
939
768
626
530
Otras Ingresos (Gastos) No Operativos
13
0
0
--
--
--
Ingreso antes de impuestos
310
300
214
9
20
9
Gasto por Impuesto a la Renta
64
-118
8
5
3
2
Ingreso Neto
246
418
206
4
16
6
Crecimiento de la Utilidad Neta
-41%
103%
5,050%
-75%
167%
-45%
Acciones en Circulación (Diluidas)
70.66
73.89
73.63
69.9
68.6
65.9
Cambio de Acciones (YoY)
-4%
0%
5%
2%
4%
6%
EPS (Diluido)
3.48
5.66
2.8
0.07
0.24
0.1
Crecimiento de EPS
-39%
102%
3,900%
-71%
140%
-47%
Flujo de efectivo libre
407
296
36
-38
-190
-82
Flujo de efectivo libre por acción
--
--
--
--
--
--
Margen bruto
71.47%
69.77%
68.29%
61.68%
68.48%
64.38%
Margen de operación
17.29%
14.87%
12.96%
2.83%
11.47%
5.64%
Margen de beneficio
9.75%
20.18%
12.13%
0.3%
1.45%
0.66%
Margen de flujo de caja libre
16.14%
14.29%
2.12%
-2.91%
-17.3%
-9.07%
EBITDA
523
388
292
100
183
106
Margen de EBITDA
20.74%
18.73%
17.2%
7.66%
16.66%
11.72%
D&A para EBITDA
87
80
72
63
57
55
EBIT
436
308
220
37
126
51
Margen de EBIT
17.29%
14.87%
12.96%
2.83%
11.47%
5.64%
Tasa de Impuesto Efectiva
20.64%
-39.33%
3.73%
55.55%
15%
22.22%
Estadísticas clave
Cierre Anterior
$240.82
Precio de apertura
$241.63
Rango del día
$241.63 - $249.47
Rango de 52 semanas
$230.05 - $354.88
Volumen
776.0K
Volumen promedio
829.9K
EPS (TTM)
3.40
Rendimiento de dividendos
--
Cap. de mercado
$17.0B
¿Qué es PODD?
Insulet Corp. is a medical device company, which engages in the development, manufacture, and marketing of an insulin infusion system for people with insulin-dependent diabetes. The company is headquartered in Acton, Massachusetts and currently employs 3,900 full-time employees. The company went IPO on 2007-05-15. The company is primarily engaged in the development, manufacture and sale of its continuous insulin delivery systems for people with insulin-dependent diabetes. The Omnipod System includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5), the Omnipod DASH Insulin Management System, and the Omnipod Insulin Management System. The Omnipod platform offers continuous insulin delivery that provides various benefits of insulin pump therapy in a way without the need for external tubing required with conventional pumps. The small, lightweight, self-adhesive disposable tubeless Omnipod device (Pod), can be worn in multiple locations, including the abdomen, hip, back of upper arm, upper thigh, or lower back, and delivers insulin into the body through a small flexible tube. The company also produces pods for Amgen for use in the Neulasta Onpro kit, a delivery system for Amgen’s Neulasta to help reduce the risk of infection after intense chemotherapy.